Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13D Filing: Farallon Capital and Nexvet Biopharma PLC (NVET)

Page 1 of 68

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Akubra Investors 0 1,046,345 0 1,046,345 1,046,345 8.7%
Bushranger Funding 0 1,128,440 0 1,128,440 1,128,440 9.4%
Ute Holdings 0 1,148,911 0 1,148,911 1,148,911 9.6%
Farallon Partners 0 2,594,576 0 2,594,576 2,594,576 21.1%
NGP 0 153,098 0 153,098 153,098 1.3%
Farallon Capital Management 0 153,098 0 153,098 153,098 1.3%
Farallon AA GP 0 313,036 0 313,036 313,036 2.6%
Farallon Partners GP VI 0 262,986 0 262,986 262,986 2.2%
Philip D. Dreyfuss 0 3,323,696 0 3,323,696 3,323,696 26.7%
Michael B. Fisch 0 3,323,696 0 3,323,696 3,323,696 26.7%
Richard B. Fried 0 3,323,696 0 3,323,696 3,323,696 26.7%
Daniel J. Hirsch See Item 0 0 0 0 0 0.0%
David T. Kim 0 3,323,696 0 3,323,696 3,323,696 26.7%
Monica R. Landry 0 3,323,696 0 3,323,696 3,323,696 26.7%
Michael G. Linn 0 3,323,696 0 3,323,696 3,323,696 26.7%
Ravi K. Paidipaty 0 3,323,696 0 3,323,696 3,323,696 26.7%
Rajiv A. Patel 9,840 3,323,696 9,840 3,323,696 3,333,176 26.8%
Thomas G. Roberts, Jr 0 3,323,696 0 3,323,696 3,323,696 26.7%
William Seybold 0 3,323,696 0 3,323,696 3,323,696 26.7%
Andrew J. M. Spokes 0 3,323,696 0 3,323,696 3,323,696 26.7%
John R. Warren 0 3,323,696 0 3,323,696 3,323,696 26.7%
Mark C. Wehrly 0 3,323,696 0 3,323,696 3,323,696 26.7%
Thomas Steyer
Thomas Steyer
Farallon Capital

Page 1 of 68 – SEC Filing

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC  20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1 )   *
Nexvet Biopharma public limited company
(Name of Issuer)
Ordinary Shares, nominal value $0.125 per share
(Title of Class of Securities)
G6503X109
(Cusip Number)
Michael B. Fisch
Farallon Capital Management, L.L.C.
One Maritime Plaza, Suite 2100
San Francisco, California 94111
(415) 421-2132
(Name, Address, and Telephone Number of Person
Authorized to Receive Notices and Communications)
April 12, 2017
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [   ].
Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See Section 240.13d-7 for other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
(Continued on following pages)
Follow Nexvet Biopharma Plc (NASDAQ:NVET)
Trade (NASDAQ:NVET) Now!
Page 1 of 68